Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_1
6
86%

Phase Distribution

6

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
6(85.7%)
Phase 2Efficacy & side effects
1(14.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 16 (85.7%)
Phase 21 (14.3%)

Trials by Status

terminated229%
withdrawn114%
completed457%

Recent Activity

0 active trials
Showing 5 of 7
withdrawnphase_1

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis

NCT03481842
completedphase_1

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

NCT01225302
completedphase_1

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

NCT01413893
terminatedphase_2

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

NCT01365910
terminatedphase_1

A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

NCT01506934
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03481842Phase 1

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis

Withdrawn
NCT01225302Phase 1

A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT01413893Phase 1

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Completed
NCT01365910Phase 2

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Terminated
NCT01506934Phase 1

A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Terminated
NCT01381341Phase 1

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

Completed
NCT01401933Phase 1

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7